Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Brian I. Rini

Hematology Oncology | Hematology | Oncology
Vanderbilt Health Clinicians, LLC
3601 The Vanderbilt Clinic, 
Nashville, TN 
Accepting New Patients
Offers Telehealth

Distinguished in WT1-Related Wilms Tumor Syndromes
Vanderbilt Health Clinicians, LLC
3601 The Vanderbilt Clinic, 
Nashville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Brian Rini is a Hematologist Oncology specialist and a Hematologist in Nashville, Tennessee. Dr. Rini is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Prostatectomy. Dr. Rini is currently accepting new patients.

His clinical research consists of co-authoring 422 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in TN
Hospital Affiliations
Vanderbilt University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

VANDERBILT HEALTH CLINICIANS, LLC
3601 The Vanderbilt Clinic, Nashville, TN 37232
Call: 615-322-3000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


9 Clinical Trials

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drug: Adavosertib
Study Phase: Phase 2
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drug: SRF388
Study Phase: Phase 1
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Enrollment Status: Completed
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination With Axitinib Versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients With Metastatic Renal Cell Carcinoma
Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination With Axitinib Versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients With Metastatic Renal Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: June 25, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Anti-OX40 Antibody PF-04518600, Axitinib
Study Phase: Phase 2
A Single-arm Phase II Trial of Intermittent Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
A Single-arm Phase II Trial of Intermittent Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Enrollment Status: Completed
Publish Date: March 18, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase Ib Trial of Neoadjuvant Durvalumab (MEDI4736) +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
A Phase Ib Trial of Neoadjuvant Durvalumab (MEDI4736) +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: March 18, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study of the Efficacy and Safety of Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer After Treatment With Pd-1 or Pd-L1 Inhibitors
A Phase II Study of the Efficacy and Safety of Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer After Treatment With Pd-1 or Pd-L1 Inhibitors
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Drug: Axitinib
Study Phase: Phase 2
A Phase l Open-Label, Dose Escalation and Cohort Expansion Study, to Assess the Safety and Activity of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC) and Advanced or Metastatic Ovarian Clear Cell Carcinoma (OCCC)
A Phase l Open-Label, Dose Escalation and Cohort Expansion Study, to Assess the Safety and Activity of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC) and Advanced or Metastatic Ovarian Clear Cell Carcinoma (OCCC)
Enrollment Status: Terminated
Publish Date: June 04, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

422 Total Publications

Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma.
Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 29, 2025
View All 422 Publications
Similar Doctors
Kathryn E. Beckermann
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kathryn E. Beckermann
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kathryn E. Beckermann
Hematology Oncology | Hematology | Oncology

Tennessee Oncology PLLC

4488 Carothers Pkwy, Suite 300, 
Franklin, TN 
 (15.4 miles away)
615-591-4764
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kathryn Beckermann is a Hematologist Oncology specialist and a Hematologist in Franklin, Tennessee. Dr. Beckermann is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, and Adult Soft Tissue Sarcoma. Dr. Beckermann is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kristin Ancell
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kristin Ancell
Hematology | Oncology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (0.1 miles away)
615-322-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kristin Ancell is a Hematologist and an Oncologist in Nashville, Tennessee. Dr. Ancell is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Melanoma, Neuroendocrine Tumor, Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Gastrostomy.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Kerry R. Schaffer
Hematology Oncology | Oncology | Hematology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Kerry R. Schaffer
Hematology Oncology | Oncology | Hematology

Vanderbilt Health Clinicians, LLC

3601 The Vanderbilt Clinic, 
Nashville, TN 
 (0.1 miles away)
615-322-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kerry Schaffer is a Hematologist Oncology specialist and an Oncologist in Nashville, Tennessee. Dr. Schaffer is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Chromophobe Renal Cell Carcinoma, and WT1-Related Wilms Tumor Syndromes. Dr. Schaffer is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rini's expertise for a condition
ConditionClose
  • Elite
  • Nephrectomy
    Dr. Rini is
    Elite
    . Learn about Nephrectomy.
    See more Nephrectomy experts
  • Renal Cell Carcinoma (RCC)
    Dr. Rini is
    Elite
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • Distinguished
  • Adult Soft Tissue Sarcoma
    Dr. Rini is
    Distinguished
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Bladder Cancer
    Dr. Rini is
    Distinguished
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Rini is
    Distinguished
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Clear Cell Sarcoma
    Dr. Rini is
    Distinguished
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Wilms Tumor 2
    Dr. Rini is
    Distinguished
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Muscle Invasive Bladder Cancer
    Dr. Rini is
    Distinguished
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
View All 10 Distinguished Conditions
  • Advanced
  • Familial Prostate Cancer
    Dr. Rini is
    Advanced
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Metastatic Brain Tumor
    Dr. Rini is
    Advanced
    . Learn about Metastatic Brain Tumor.
    See more Metastatic Brain Tumor experts
  • Non-Muscle Invasive Bladder Cancer
    Dr. Rini is
    Advanced
    . Learn about Non-Muscle Invasive Bladder Cancer.
    See more Non-Muscle Invasive Bladder Cancer experts
  • Posterior Fossa Tumor
    Dr. Rini is
    Advanced
    . Learn about Posterior Fossa Tumor.
    See more Posterior Fossa Tumor experts
  • Primitive Neuroectodermal Tumor (PNET)
    Dr. Rini is
    Advanced
    . Learn about Primitive Neuroectodermal Tumor (PNET).
    See more Primitive Neuroectodermal Tumor (PNET) experts
  • Upper Tract Urothelial Carcinoma (UTUC)
    Dr. Rini is
    Advanced
    . Learn about Upper Tract Urothelial Carcinoma (UTUC).
    See more Upper Tract Urothelial Carcinoma (UTUC) experts
  • Experienced
  • Bone Tumor
    Dr. Rini is
    Experienced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Brain Tumor
    Dr. Rini is
    Experienced
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Breast Cancer
    Dr. Rini is
    Experienced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Deep Vein Thrombosis
    Dr. Rini is
    Experienced
    . Learn about Deep Vein Thrombosis.
    See more Deep Vein Thrombosis experts
  • Dehydration
    Dr. Rini is
    Experienced
    . Learn about Dehydration.
    See more Dehydration experts
  • Hemangioblastoma
    Dr. Rini is
    Experienced
    . Learn about Hemangioblastoma.
    See more Hemangioblastoma experts
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved